Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer

被引：34

作者：

Gelmon, K. A.

Hirte, H. W.

Robidoux, A.

Tonkin, K. S.

Tischkowitz, M.

Swenerton, K.

Huntsman, D.

Carmichael, J.

Macpherson, E.

Oza, A. M.

机构：

[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[2] Juravinski Canc Ctr, Hamilton, ON, Canada

[3] CHUM Hotel Dieu, Montreal, PQ, Canada

[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[5] McGill Univ, Montreal, PQ, Canada

[6] AstraZeneca, Macclesfield, Cheshire, England

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.3002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3002

引用

页数：1